AGM Statement
22/05/2024 07:00
For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20240522:nRSV3503Pa&default-theme=true
RNS Number : 3503P Niox Group PLC 22 May 2024
NIOX GROUP PLC
("NIOX" or the "Company" and, together with its subsidiaries, the "Group")
AGM Statement
Oxford, UK - 22 May 2024: NIOX Group plc (AIM: NIOX), a medical device company
focused on point of care asthma diagnosis and management, is holding its
Annual General Meeting today at the Hayakawa Building, Edmund Halley Road,
Oxford Science Park. Oxford OX4 4GB.
Trading Update
We are pleased to report that our business has continued to perform strongly
in the year to date, in line with management expectations.
In January 2024, NIOX settled returns claims amounting to £0.4m in relation
to the discontinued business. The unaudited cash balance as at 30 April 2024
was £23.7m (31 December 2023: £19.9m), with no bank borrowings.
NIOX expects to give a trading update in relation to the six months ended 30
June 2024 around the middle of July.
Contacts:
NIOX Tel: +44 (0) 1865 405 560
Ian Johnson, Executive Chairman
Michael Roller, Chief Financial Officer
Singer Capital Markets (Nominated Adviser and Broker) Tel: +44 (0) 20 7496 3000
Aubrey Powell / Jen Boorer / James Todd
Investec Bank plc (Joint Broker) Tel: +44 (0) 20 7597 4000
Edward Knight / Bruce Garrow / Lydia Zychowska
About NIOX
Our mission is to improve asthma diagnosis and management by greater patient
access to FeNO testing. Asthma is one of the biggest healthcare issues
globally with 340 million sufferers, many of whom are undiagnosed or are
misdiagnosed. The Group is engaged in the design, development, and
commercialisation of medical devices for the measurement of FeNO, a precise
biomarker for asthma. Our market leading device, NIOX VERO®, is increasingly
recognised by healthcare professionals as an important tool to improve the
diagnosis and management of asthma. NIOX VERO® is also the device of choice
by leading clinical research organisations for respiratory studies.
NIOX provides products and services via its direct sales organisation and
extensive distributor network in 50 countries. For more information, please
visit www.niox.com (http://www.niox.com)
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
or visit
www.rns.com (http://www.rns.com/)
.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
. END AGMGZGZKVMKGDZM